Crossmark

Lower doses of dacarbazine (modified BEACODD) as a safer strategy with equal effectiveness in an intensive treatment protocol of Hodgkin's lymphoma: a preliminary retrospective analysis of a single public center in Brazil

Crossref DOI link: https://doi.org/10.1016/j.htct.2024.06.003

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Dulley, Larissa Hilario

Braga, Arthur Gomes Oliveira https://orcid.org/0000-0001-9223-9139
Rodrigues, Guilherme Garcia

Fortier, Sergio Costa

Chiattone, Carlos Sérgio

da Silveira, Talita Maira Bueno
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2024-08-28
More Information

This article is maintained by: Elsevier

Article Title: Lower doses of dacarbazine (modified BEACODD) as a safer strategy with equal effectiveness in an intensive treatment protocol of Hodgkin's lymphoma: a preliminary retrospective analysis of a single public center in Brazil

Journal Title: Hematology, Transfusion and Cell Therapy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.htct.2024.06.003

Content Type: article

Copyright: © 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below